External broker reports(aggregated public sources), Wilsons Advisory

Wilsons Advisory

External broker reports(aggregated public sources)

Wilsons has a distinguished history in financial services that spans over 125 years. Today, the group has significant capabilities in private wealth management, corporate finance, research and investment strategy, and institutional sales. Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

<ul><li>Mach7 provided a 3Q24 update today. Update was largely in line with expectations, noting ARR run-rate of $22.3M (Mar-q end), sits ahead of WILSe FY24 ARR of $20.1M.</li><li>Sales orders for the quarter of $7.4M now arm Mach7 with $56.9M in total sales orders for the year – tracking well to beat their FY24 target of $60M.</li><li>Positive cash flow for the quarter ($1.4M) instills confidence in still meeting cash flow breakeven for FY24. </li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Mach7 provided a 3Q24 update today. Update was largely in line with expectations, noting ARR run-rate of $22.3M (Mar-q end), sits ahead of WILSe FY24 ARR of $20.1M.Sales orders for the quarter of $7.4M now arm Mach7 with $56.9M in total sales orders for the year – tracking well to beat their FY24 target of $60M.Positive cash flow for the quarter ($1.4M) instills confidence in still meeting cash flow breakeven for FY24. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

<ul><li>We maintain our OVERWEIGHT rating and $1.05/sh PT on Mach7.</li><li>Mach7 has been in stasis whilst their capital -&gt; subscription contract transition has occurred faster than expected, with FY24 revenue and earnings taking a blow (a near term impact).</li><li>As we look out to the remainder of FY24, we expect share price to be driven by new contract wins, which will see M7T deliver on &gt;$60M in total sales orders for the year, whilst sticking to cash-flow breakeven.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

We maintain our OVERWEIGHT rating and $1.05/sh PT on Mach7.Mach7 has been in stasis whilst their capital -&gt; subscription contract transition has occurred faster than expected, with FY24 revenue and earnings taking a blow (a near term impact).As we look out to the remainder of FY24, we expect share price to be driven by new contract wins, which will see M7T deliver on &gt;$60M in total sales orders for the year, whilst sticking to cash-flow breakeven.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Mach7 Technologies (M7T) - 1H24: Launch Pending

<ul><li>We maintain our OVERWEIGHT rating with an updated $1.05/sh PT on Mach7.</li><li>As expected, Mach7 have announced an FY24 revenue downgrade owing to an increasing amount of healthcare facilities opting for subscription contracts vs capital contracts, removing the 50-60% of contract value that they would otherwise receive up front.</li><li>This is not surprising, and to be frank, was well overdue.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

We maintain our OVERWEIGHT rating with an updated $1.05/sh PT on Mach7.As expected, Mach7 have announced an FY24 revenue downgrade owing to an increasing amount of healthcare facilities opting for subscription contracts vs capital contracts, removing the 50-60% of contract value that they would otherwise receive up front.This is not surprising, and to be frank, was well overdue.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Mach7 Technologies (M7T) - Subscribing for the Long-Term

<ul><li>Mach7 provided a Q124 update today. As expected from recently announced deals, the company reported $33.5M in total sales orders for the quarter, importantly representing 70% of their FY24 target sales orders of $48M.</li><li>It is becoming increasingly clear that both new and renewal customers are opting for a subscription-based license model, rather than a capital model, which bodes well for Mach7 in the long-term (reaching ARR covering 100% of their opex sooner), however, as we have pointed out, creates uncertainty in hitting their revenue target in the near-term.</li><li>Management appear confident in FY24 sales pipeline, already supported by a &gt;30% uplift in ARR in 12 months’ time (CARR reported at $25.5M).</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Mach7 provided a Q124 update today. As expected from recently announced deals, the company reported $33.5M in total sales orders for the quarter, importantly representing 70% of their FY24 target sales orders of $48M.It is becoming increasingly clear that both new and renewal customers are opting for a subscription-based license model, rather than a capital model, which bodes well for Mach7 in the long-term (reaching ARR covering 100% of their opex sooner), however, as we have pointed out, creates uncertainty in hitting their revenue target in the near-term.Management appear confident in FY24 sales pipeline, already supported by a &gt;30% uplift in ARR in 12 months’ time (CARR reported at $25.5M).Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Mach7 Technologies (M7T) - Q124: First Look

<ul><li>We maintain our OVERWEIGHT rating and $1.15/sh PT on Mach7.</li><li>Going into 1Q24, the market was aware that the company would deliver record sales orders, owing to recent announcements.</li><li>What we took from the update is that increasingly, new contract signings as well as renewals will likely look to preference subscription contracts, despite previous assumptions of a slower transition away from capital contracts (particularly in regards to contract renewals). </li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

We maintain our OVERWEIGHT rating and $1.15/sh PT on Mach7.Going into 1Q24, the market was aware that the company would deliver record sales orders, owing to recent announcements.What we took from the update is that increasingly, new contract signings as well as renewals will likely look to preference subscription contracts, despite previous assumptions of a slower transition away from capital contracts (particularly in regards to contract renewals). Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Mach7 Technologies (M7T) - Utilising X-Ray Vision

Australia

Mach7 Technologies Limited designs and develops healthcare software solutions. The Company offers enterprise imaging platform, vendor neutral archive, communication workflow engine, and managed data solutions. Mach7 Technologies operates in Australia.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Mach7 Technologies (M7T AU)

M7T 3Q24: First Look

Mach7 provided a 3Q24 update today. Update was largely in line with expectations, noting ARR run-rate of $22.3M (Mar-q end), sits ahead of WILSe...

Wilsons Advisory

Mach7 Technologies (M7T) - 1H24: Launch Pending

Mach7 has been in stasis whilst their capital -> subscription contract transition has occurred faster than expected, with FY24 revenue and earnings...

Wilsons Advisory

Mach7 Technologies (M7T) - Subscribing for the Long-Term

The market’s reaction was neutral because the revenue downgrade was countered by the fact that Mach7 increased FY24E sales order guidance by 25%,...

Wilsons Advisory

Mach7 Technologies (M7T) - Q124: First Look

Management appear confident in FY24 sales pipeline, already supported by a >30% uplift in ARR in 12 months’ time (CARR reported at $25.5M).

Wilsons Advisory

Mach7 Technologies (M7T) - Utilising X-Ray Vision

We maintain our OVERWEIGHT rating and $1.15/sh PT on Mach7. Going into 1Q24, the market was aware that the company would deliver record sales...

Wilsons Advisory

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)